SMN1 and neoplasm: The higher release at the beginning of the treatment (Figure 2b) might account for the rapid onset of SMA–TFA efficacy in the in vivo experiments, where a reduction of tumor size is observed within the first 2 days with a slight reduction in body weight (Figure 4b).